Brief: Tenax Therapeutics To Amend Level-2 Enrollment Criteria
08/10/2026 23:21
BRIEF-Tenax Therapeutics To Amend Level-2 Enrollment Criteria Oct 8 (Reuters) - Tenax Therapeutics Inc TENX.O:
TENAX THERAPEUTICS - TO AMEND LEVEL-2 ENROLLMENT CRITERIA - SEC FILING
TENAX THERAPEUTICS - REQUESTS TYPE C MEETING WITH FDA ON LEVOSIMENDAN DEVELOPMENT - SEC FILING
TENAX THERAPEUTICS - TEMPORARILY PAUSES LEVEL-2 ENROLLMENT FOR TNX-103 IN PH-HFPEF - SEC FILING
TENAX THERAPEUTICS: ENROLLMENT MAY RESUME AT EACH SITE AS AMENDED PROTOCOL GOES INTO EFFECT
Source text: [ID:n0001193125-26-417939]
Further company coverage: TENX.O
((Reuters.Briefs@thomsonreuters.com;))